Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sorafenib combined with tislelizumab for first-line unresectable hepatocellular carcinoma
ChiCTR2100050076Phase 2Recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Safety and tolerability, Objective response rate and 2 more. Started Jan 2021; status: recruiting.
02
Drugs
sorafenibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100050076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050076.